Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/21/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Scott A. Siegel Ph.D.

Wrong Dr. Scott A. Siegel Ph.D.?

Vice President of Business Develo...

Phone: (908) ***-**** ext. ***  
Institute for Life Science Entrepreneurship
1000 Morris Ave STEm Bldg.
Union , New Jersey 07083
United States

Company Description: ILSE is an independent non-profit translational research institute founded in 2014. The Institute's mission is to identify and advance early life science innovation...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Yale University School of Medicine
  • Bachelor of Science degree , biology
    State University of New York , College at New Paltz
  • MBA , communications
    Wharton School
  • Ph.D. , Biochemistry
    SUNY
  • Ph.D. , Biochemistry
    SUNY Downstate Medical Center
  • Ph.D. , biochemistry
    SUNY Downstate Medical
  • Ph.D. , biochemistry
    State University of New York
76 Total References
Web References
Scott ...
ilsebio.com [cached]
Scott Siegel
...
SCOTT A. SIEGEL, PHD
Scott Siegel, PhD, Vice ...
ilsebio.com [cached]
Scott Siegel, PhD, Vice President of Business Development for Institute for Life Science Entrepreneurship (ILSE) addressed attendees of the organization's second stakeholder forum. Siegel explained how the organization planned to build on early successes and further contribute to the area's life sciences industry and ILSE's mission to accelerate life sciences innovation in medicine, devices and other technologies to improve human health.
...
For information, contact Scott Siegel, PhD, at (908) 737-1922 x104 or ssiegel@ilsebio.com. Visit ILSE online at www.ilsebio.com.
Photos taken during ILSE 2nd Stakeholder Forum, March 8, 2016:
GroupPhoto-Richardson-Siegel-Bostian-Cypess-Connelly
Pictured from left: Dr. Thomas Richardson, VP, Strategic Initiatives, BioNJ; Dr. Scott Siegel, Business Development, ILSE; Dr. Keith Bostian, Interim CEO, ILSE, and Dean, New Jersey Center for Science, Technology & Mathematics (NJCSTM) and Office of Technology Transfer; Dr. Raymond Cypess, CEO, ATCC; Phillip Connelly, EVP, Kean University.
SCOTT A. SIEGEL, ...
ilsebio.com [cached]
SCOTT A. SIEGEL, PHD
...
SCOTT A. SIEGEL, PHD VP BUSINESS DEVELOPMENT
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.
Scott A. Siegel, PhD ...
www.ilsebio.com [cached]
Scott A. Siegel, PhD
Scott A. Siegel, ...
www.ilsebio.com [cached]
Scott A. Siegel, PhD VP Business Development
...
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.
Other People with the name "Siegel":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304